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included in the top 10. Next, 185 patients evaluated the importance of 27 attributes 
in the BWS. Effect on disease progression was most important (RIS= 9.6), followed 
by quality of life (9.2), relapse rate (7.8), severity of side effects (7.6), relapse severity 
(7.4), current MS symptoms (7.3), plaque development (7.3), and safety (6.0). Effect 
on disease progression was 1.8 times more important than influence on lifestyle 
(5.3). Subgroup analysis showed that DMD naïve patients found side effect-related 
attributes far more important than DMD experienced patients. ConClusions: 
Using a thorough method, this study reveals that patients value effectiveness and 
unwanted effects most. Also, heterogeneity was observed in different subgroups. 
Clinicians should be aware of the average preference values and that DMD attributes 
are valued differently by different patients. Person-centred clinical decision-making 
would be needed and requires elicitation of individual preferences.
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objeCtives: NICE has suggested that patient preference plays a role in physician 
selection of some Multiple Sclerosis (MS) treatments, but existing patient prefer-
ence surveys are developed using literature rather than patient input. Aims of this 
study were: combine existing literature with patient interviews to develop a dis-
crete choice experiment (DCE) to assess patient preference for MS treatments and 
compare and contrast this information to critically appraise the mixed methods 
approach. Methods: A literature review was conducted to understand patient pref-
erence for attributes of existing MS treatments and inform development of a DCE. 
12 one-to-one telephone interviews were conducted with MS patients. Interviews 
comprised two parts; understanding treatment attributes of importance to patients, 
and detailed cognitive appraisal of the DCE. Team-based framework analysis was 
conducted using interview audio files. Results: Literature and patients interviewed 
generally agreed on key treatment attributes. Although brain lesions were identified 
from literature as a clinical marker, only one patient expressed this as important and 
others either did not understand it or the information was not shared by their clini-
cian. In agreement with literature, patients shared that side effects impacting their 
quality of life were most important, for example fatigue and infection. Feedback on 
the DCE highlighted the importance of consistency between the wording length of 
the attribute level descriptions; patients considered longer descriptions correlated 
with a ‘worse’ level. Interviews also identified questions where language refinement 
was required to improve comprehensiveness. Patients had little knowledge of dis-
ease severity scores contrary to suggestions in the literature, but as disease severity 
was an important concept, this definition was changed. ConClusions: Combining 
patient interviews and existing literature to develop a DCE can have advantages over 
using literature alone: greater confidence that attributes are important to patients, 
early refinement of language and an understanding of patients’ thought processes 
during DCE completion.
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objeCtives: The caregiver-completed Hyperphagia Questionnaire (HQ) is commonly 
used to assess food-seeking behaviours in Prader-Willi syndrome (PWS). A modified 
version, the HQ for Clinical Trials (HQ-CT), was developed and adapted for use in mul-
tinational PWS clinical trials. Methods: The 13-item HQ was reviewed and modified 
based on industry and regulatory standards. The preliminary HQ-CT was included 
in a phase 2 trial; data analysis informed psychometric evaluation and optimal scor-
ing. Further refinements were made following Food and Drug Administration (FDA), 
clinical reviews, and interviews with PWS caregivers in the United States (US). The 
final 9-item HQ-CT was culturally adapted to 10 European languages using industry 
standards for forward-back translation, followed by cognitive debriefing interviews 
(CDIs) with PWS caregivers in target countries to assess content validity. Results: 
Review of the 13-item HQ removed three items to limit content to observable behav-
iours that could change after treatment. Analysis of trial data provided support for 
an HQ-CT composite score (e.g., alpha coefficients ≥ 0.85), as well as the measure’s 
validity and responsiveness. One item was removed based on FDA recommenda-
tion, yielding a 9-item HQ-CT. Interviews with 6 PWS caregivers in the US supported 
content validity. CDIs conducted with 5 PWS caregivers (native-language speakers 
and target-country residents) tested each of the new language translations. Interview 
samples included male and female caregivers, except for the United Kingdom-English 
and the Netherlands-Dutch samples (females only). Respondent ages ranged from 23 
to 64 years across all countries. European caregivers found the HQ-CT content relevant 
and clear. However, there was some difficulty understanding the term ‘hyperphagia’; 
additional text was added to clarify this word. ConClusions: The development of 
the HQ-CT and its adaptation to 10 European languages, with input from 56 caregivers, 
has produced a valuable instrument for assessing food-seeking behaviours in PWS 
clinical trials in the US and Europe.
PND75
AssociAtioN BetweeN self-ADMiNistereD exPANDeD DiseAse severity 
scAle (eDss) AND MUltiPle sclerosis iMPAct scAle (Msis-29): resUlts 
froM the BUrDeN of illNess iN PAtieNts with MUltiPle sclerosis iN 
fiNlAND (DefeNse) stUDy
Viita A1, Hämäläinen P2, Ruutiainen J2, Hahl J3, Nissinen H1
1Novartis Finland Oy, Espoo, Finland, 2Masku Neurological Rehabilitation Centre, Masku, Finland, 
3AT Medical Affairs Consulting Oy (Medaffcon), Espoo, Finland
PND70
A coMPArisoN of stAteD PrefereNces for iNjectABle DiseAse-
MoDifyiNg treAtMeNts for MUltiPle sclerosis: coMPliANt vs.  
NoN-coMPliANt PAtieNts
Poulos C1, Kinter E2, Posner J1, Van Beek J2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Biogen, Zug, Switzerland
objeCtives: Medication compliance with injectable disease-modifying treatments 
(DMTs) for multiple sclerosis (MS) is sub-optimal, with published compliance rates 
ranging from 27% to 83%. This study quantified MS patients’ preferences for features 
of injectable DMTs, and examined whether non-compliant patients have different 
preferences than compliant patients. Methods: Adults with self-reported physi-
cian-diagnoses of MS in Germany (N= 189), the United Kingdom (UK) (N= 100) and 
France (N= 100) completed an online discrete choice experiment survey. Treatment-
experienced respondents reported their level of compliance with their current (or 
most recent) MS medicine and two groups were created: compliant respondents 
(who reported always taking medicine exactly as prescribed) and non-compliant 
respondents (who reported missing less than half, about half, or more than half of 
doses). Respondents were presented with a series of nine treatment-choice ques-
tions wherein hypothetical treatments were described in terms of six attributes. 
Mixed-logit regression parameters were used to calculate preference weights, or 
utilities, of attribute levels and relative importance or, utility differences, of changes 
in attributes for both the compliant and non-compliant respondents. Wald- and 
t-tests of the differences in preferences were conducted. Results: In Germany, the 
UK and France, 81%, 37%, and 73% of the sample reported being compliant, respec-
tively. The relative importance of delaying disability progression for 3 years was 2.7 
times more important among the compliant group than the non-compliant group 
in Germany and the UK (P< 0.05) and 1.1 times more important in France. Among 
compliant respondents, improvements in injection frequency (from 30 to 2 injections 
per month) relative to this improvement in efficacy were 1.5, 6.0, and 2.6 times more 
important to the non-compliant group than the compliant group in Germany, the UK, 
and France. ConClusions: Reductions in injection frequency are relatively more 
important to non-compliant MS patients than to compliant patients, while delay-
ing disability progression was relatively more important to compliant MS patients.
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objeCtives: To estimate patient preferences for relapsing-remitting multiple sclero-
sis (RRMS) treatments Methods: Patients in the United States who reported receiv-
ing a diagnosis of MS from their physician completed a Web-based discrete-choice 
experiment (DCE) survey that included questions on treatment experience and adher-
ence. The survey presented 10 DCE questions in which respondents were asked to 
choose between pairs of hypothetical MS treatment profiles. The profile attributes of 
the treatments were informed by a literature search and clinician input, and tested in 
patient interviews. Attributes included: change in MS progression and years between 
relapses; risk of serious infection; delivery method and frequency of administration; 
and chance of flu-like and gastrointestinal (GI) symptoms. The profiles in the DCE 
questions were based on an experimental design with known statistical properties. 
Random-parameters logit was used to estimate preferences. Results: The sample 
included 301 patients with RRMS: 81% were female; mean age was 54 years; 56% rated 
their disability level as “normal” or “mild”; and 79% reported currently receiving a 
prescription MS treatment. Nineteen percent reported stopping or skipping treatment 
doses due to flu-like symptoms and 9% due to GI symptoms. Respondents placed the 
greatest decision weight on reducing the chance of MS progression and risk of serious 
infection, as well as on the mode and frequency of administration. Followed by daily 
pills, an intravenous (IV) administration every 6 months was preferred over IV every 
month and injections 3 times per week (P < 0.05). Respondents reported being most 
likely to adhere to either daily pills or IV administration every 6 months (39% and 29% 
of patients, respectively). ConClusions: Patients with RRMS reported that treatment 
preferences were influenced by efficacy, reduced side effects, and less burdensome 
modes of administration. Side effects and mode of administration also influenced 
reported likelihood of treatment adherence.
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objeCtives: More than 10 disease modifying drugs (DMDs) are available for relaps-
ing-remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS). Poor 
adherence to DMDs often results in suboptimal (cost-)effectiveness. Understanding 
patients’ preferences for DMD and incorporating them in clinical decision-making 
can contribute to adherence to DMDs. This study aims first to identify the full spec-
trum of DMD attributes and second to quantify their relative importance among 
patients. Methods: First, 3 focus groups with RRMS patients were conducted using 
a nominal group technique to explore attributes for decision-making. Through indi-
vidual generation and discussion of attributes, a full list was created and patients 
selected their 10 most important attributes. Second, a best-worst scaling (BWS) was 
conducted in a larger RRMS/CIS patient group to prioritize attributes. Attributes’ 
mean relative importance scores (RIS) were obtained with Hierarchical Bayes analy-
sis. Results: Nineteen patients participated in the focus groups. A list of 34 attrib-
utes was derived of which 7 were excluded from the BWS because they were never 
